MODERN METHODS FOR PREDICTING COGNITIVE DISORDERS IN PARKINSON'S DISEASE
DOI registered with Crossref
https://doi.org/10.37547/ijmsphr/Volume05Issue12-07
Keywords
Parkinson's disease
cognitive disorders
dementia
Abstract
In Parkinson's disease (PD), among the clinical and symptomatic manifestations of the disease in recent years, attention has been increasingly paid to the so-called non-motor symptoms, that is, cognitive disorders. In PD, cognitive disorders can manifest themselves in the form of a decrease in executive, visual, and visuospatial activity and memory impairment from mild to severe dementia. Cognitive impairments of a subjective and objective nature are often found at the level of early and mild manifestations. In such situations, it is important to develop a strategy for predicting the progression of cognitive disorders and developing methods for their prevention. Long-term and multicenter studies conducted over the past 30-40 years have shown that after the diagnosis of PD, dementia develops after ten courses of the underlying disease. This, in turn, aggravates the already complex course of PD with a pronounced decrease in the quality of life of patients.
Downloads
Download data is not yet available.
References
1
Clinical diagnostic criteria for dementia associated with Parkinson's disease. / M. Emre, D. Aarsland, R. Brown, et al. // Mov. Disord. – 2017;22(12):1689-1707
2
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. / I. Litvan, J.G. Goldman, A.I. Tröster, et al. // Mov. Disord. - 2016;27(3):349-356.
3
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. / P. Svenningsson, E. Westman, C. Ballard, D. Aarsland. // Lancet Neurol. - 2015;11(8):697-707.
4
Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. / K.F. Pedersen, J.P. Larsen, O.B. Tysnes, G. Alves. // JAMA Neurol. – 2015;70:580–586.
5
The distinct cognitive syndromes of Parkinson's disease: 5-year follow-up of the CamPaIGN cohort. / C.H. Williams-Gray, J.R. Evans, A. Goris, et al. // Brain. - 2011;132(11):2958-2969.
6
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. / C.H. Williams-Gray, S.L. Mason, J.R. Evans, et al. // J. Neurol. Neurosurg. Psychiatry. - 2016;84(11):1258-1264.
7
Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. / G. Santangelo, C. Vitale, M. Picillo, et al. // Parkinsonism Relat Disord. - 2015;21(10):1219-1226.
8
Longitudinal study of normal cognition in Parkinson's disease. / K. Pigott, J. Rick, S.X. Xie, et al. // Neurology. - 2015;85(15):1276-1282.
9
Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. / C.H. Williams-Gray, A. Hampshire, T.W. Robbins, et al. // J. Neurosci. - 2017;27(18):4832-4838.
10
Kehagia A.A., Barker R.A., Robbins T.W. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. // Neurodegener Dis. - 2013;11(2):79-92.
11
Different PD-MCI criteria and risk of dementia in Parkinson's disease: a 4-year longitudinal study. / K.L. Wood, D.J. Myall, L. Livingston, et al. // NPJ Parkinsons Dis. - 2016;2:15027.
12
Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. / D.H. Ffytche, J.B. Pereira, C. Ballard, et al. // J Neurol Neurosurg Psychiatry. - 2017;88(4):325-331.
13
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. / D. Aarsland, K. Andersen, J.P. Larsen, et al. // Arch. Neurol. - 2015;60(3):387-392.
14
Predictors of dementia in Parkinson disease: a prospective cohort study. / J.B. Anang, J.F. Gagnon, J.A. Bertrand, et al. // Neurology. - 2016;83(14):1253-1260.
15
Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. / D.C. Backstrom, M. Eriksson Domellof, J. Linder, et al. // JAMA Neurol. - 2015;72(10):1175-1182.
16
CSF biomarkers and clinical progression of Parkinson's disease. / S. Hall, Y. Surova, A. Qhrfelt, et al. // Neurology. - 2015;84(1):57-63.
17
CSF Aβ42 predicts early-onset dementia in Parkinson's disease. / G. Alves, J. Lange, K. Blennow, et al. // Neurology. - 2014;82(20):1784-1790.
18
CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson's Disease. / M.Jr. Terrelonge, K.S. Marder, D. Weintraub, R.N. Alcalay. // J. Mol. Neurosci. - 2016;58(1):88-92.
19
COPPADIS-2015, a global--clinical evaluation, serum biomarkers, genetic studies and neuroimaging, is a prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. / D. Santos-GarcÃa, P. Mir, E. Cubo, COPPADIS Study Group., et al. // BMC Neurol. - 2016;16:26.
20
Politis M., Su P., Piccini P. Imaging of microglia in patients with neurodegenerative disorders. // Front Pharmacol. - 2012;3:96.
21
The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. / K. Wu, D. O'Keeffe, M. Politis, et al. // Brain. - 2012;135(8):2449-2457.
22
Impaired cognitive performance and hippocampal atrophy in Parkinson's disease. / D. Yildiz, S. Erer, M. ZarifoÄŸlu, et al. // Turk. J. Med. Sci. - 2015;45(5):1173-1177.
23
Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. / E. Mak, L. Su, G.B. Williams, et al. // Brain. - 2015;138(10):2974-2986.
24
Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. / J.B. Pereira, D. Aarsland, C.E. Ginestet, et al. // Hum. Brain Mapp. - 2015;36(8):2980-2995.
25
Mild cognitive impairment is linked with a faster rate of cortical thinning in patients with Parkinson's disease longitudinally. / A. Hanganu, C. Bedetti, C. Degroot, et al. // Brain. - 2014;137(4):1120-1129.
26
Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia. / B.Borroni, E. Premi, A. Formenti, et al. // Parkinsonism Relat Disord. - 2015;21(9):1049-1055.
27
Quantitative EEG analysis of executive dysfunction in Parkinson's disease. / S. Kamei, A. Morita, K. Serizawa, et al. // J. Clin. Neurophysiol. - 2016;27(3):193-197.
28
Morita A., Kamei S., Mizutani T. Relationship between slowing of the EEG and cognitive impairment in Parkinson's disease. // J. Clin. Neurophysiol. - 2016;28(4):384–387.
29
Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease. / J.H. Caviness, J.G. Hentz, C.M. Belden, et al. // J. Parkinsons Dis. - 2015;5(1):117-24.
30
30. Correlation of EEG slowing with cognitive domains in nondemented patients with Parkinson's disease. / R. Zimmermann, U. Gschwandtner, F. Hatz, et al. // Dement Geriatr Cogn Disord. 2015;39(3-4):207-14.
31
Comparison of quantitative EEG between patients with Alzheimer's disease and those with Parkinson's disease dementia. / L.C. Fonseca, G.M. Tedrus, P.N. Carvas, E.C. Machado. // Clin. Neurophysiol. - 2016;124(10):1970-1974.
32
Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. / Y. Compta, N. Ibarretxe-Bilbao, J.B. Pereira, et al. // Parkinsonism Relat Disord. - 2015;18(8):941-947.
33
Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. / Y. Compta, J.B. Pereira, J. RÃos, et al. // Parkinsonism Relat Disord. - 2013;19(8):717-724.